09:09 AM EDT, 07/02/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, on Tuesday reported the enrollment of 116 patients at the end of June in the Tigris trial.

The company enrolled nine patients in June and reported the enrollment of 35 patients in 2024 so far.

The Tigris trial is a phase 3 follow-on study designed to evaluate the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

The company said it is now working to fully enroll and finish the Tigris trial, with 34 patients required for full enrollment.

The company said there are currently 23 clinical sites for the trial.